Laboratory evaluation of inflammatory bowel disease

Current Opinion in Pediatrics

Volumn 20, Issue 5, 2008, Pages 566-570

  Wong, Allison ^a   Bass, Dorsey ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pediatric Gastroenterology Hepatology and Nutrition   (United States)

Author keywords

Fecal markers; Inflammatory bowel disease; Inflammatory bowel disease serology; Thiopurine metabolites

Indexed keywords

AZATHIOPRINE; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; MERCAPTOPURINE; SERUM ALBUMIN;

ABDOMINAL PAIN; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DRUG USE; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES; GASTROENTEROLOGY; HEALTH STATUS; HUMAN; IRRITABLE COLON; LABORATORY TEST; LIVER TOXICITY; MONITORING; PANCREATITIS; PHARMACOGENETICS; PHYSICIAN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SAMPLE; SCREENING TEST; SEROLOGY;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CLINICAL LABORATORY TECHNIQUES; COLITIS, ULCERATIVE; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; FECES; FEMALE; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; PEDIATRICS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 53549093575     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32830d3aaf     Document Type: Review

References (22)

1. Kugathasan S, Judd RH, Hoffman RG, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin : a statewide population-based study. J Pediatr 2003; 143:525-531.
2. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007; 119:1113-1119.
3. Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can J Gastroenterol 2008; 22:33-36.
4. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 99:2235-2241.
5. Mainardi E, Villanacci V, Bassotti G, et al. Diagnostic value of serological assays in pediatric inflammatory bowel disease. Digestion 2007; 75:210-214.
6. Desplat-Jego S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, antinuclear associated antineutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007; 13:2312-2318.
7. Davis MK, Andres JM, Jolley CD, et al. Antibodies to Escherichia coli outer membrane porin c in the absence of anti-Saccharomyces cerevisiae antibodies and antineutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J Pediatr Gastroenterol Nutr 2007; 45:409-413.
8. Sabery N, Bass D. Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia. Pediatrics 2007; 119:193-199.
9. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clinica Chimica Acta 2007; 381:63-68.
10. Schoepfer AM, Trummler M, Seeholzer P, et al. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32-39.
11. Sidler M, Leach S, Day AS. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis 2008; 14:359-366.
12. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102:803-813.
13. Fagerberg UL, Loof L, Lindholm J, et al. Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediat Gastroenterol Nutr 2007; 45:414-420.
14. Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103:162-169.
15. Walkiewicz D, Werlin SL, Fish D, et al. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008; 5:669-673.
16. Diamanti A, Colistro F, Basso MS, et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel disease. Inflamm Bowel Dis 2008; 13:1-7.
17. Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 414-422.
18. Seidman EG. Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD. Rev Gastroenterol Disord 2003; 3 (Suppl 1):S30-S38.
19. Temi A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease. Clin Pharmacokinet 2007; 46:187-208.
20. Ooi CY, Bohane TD, Lee D, et al. Thiopurine metabolite monitoring in pediatric inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25:941-947.
21. Morales A, Salguti S, Miao CL, Lewis JD. Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:380-385.
22. Winter JR, Gaffney D, Shapiro D, et al. Assessment of thiopurine methyl-transferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25:1069-1077.